SpyGlass Pharma, Inc. (SGP) Stock: Price, Forecast & Analyst Target
SpyGlass Pharma, Inc. (SGP) — MoonshotScore 64/100 (Fair band), calculated Nov 18, 2026. Price $30.78 (+3.71%), as of the Nov 19, 2026 trading session; market cap $1.03B.
Educational signal · not a buy or sell recommendation · How to read this
SpyGlass Pharma, Inc. · SGP · NASDAQ
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company focused on developing innovative therapeutic approaches for chronic eye conditions. Its flagship Bimatoprost Drug Pad-IOL System aims to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension during cataract surgery.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · SpyGlass Pharma (SGP)
FairWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but weak growth and a full valuation; the market is already moving on it. Business Quality: Average; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Surging.
- EPS beat 0 of the last 3 reports
- Altman Z 39.68 · Piotroski F 1
- ROE -43.0% · ROA -27.3% · current ratio 15.24
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 64 | Fair | |
| 65 | Strong | |
| 66 | Strong | |
| 66 | Strong | |
| 64 | Fair | |
| 64 | Fair |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $30.78 | |
| Change on the day | +3.71% | |
| Market capitalisation | $1.03B | — |
| Shares traded on the day | 86.4K |
Price & events
Other perspectives
Council score for SpyGlass Pharma (SGP): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Englander-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is SpyGlass Pharma (SGP), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. SpyGlass Pharma, Inc. (SGP) is listed on NASDAQ. It employs 88 people. The market values it at $1.03B.
What do the latest results show for SpyGlass Pharma (SGP)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 3 reports.
What are the financial strengths and risks for SpyGlass Pharma (SGP)?
Short answer
The MoonshotScore pillars rate balance-sheet strength, positive momentum as strengths. The distress and quality screens read Altman Z 39.68 · Piotroski F 1. Trailing ratios: ROE -43.0% · ROA -27.3% · current ratio 15.24.
Data-derived red flags
- Negative return on equity (-43.0%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at SpyGlass Pharma (SGP)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $0.00 · EPS -2.73 · 0 analysts. Current published price targets run low $37.00 · high $44.00 · consensus $40.00 · median $39.00 against a quoted price of $30.78 (as of Nov 19, 2026).
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No quarterly income statement is held for SGP.
Checked against the records this page reads, on the dates shown above.
How does SpyGlass Pharma compare with its peers?
Short answer
SpyGlass Pharma's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $61.99 Nov 18, 2026 | $1.79B | 98 5-pillar Nov 18, 2026 | |
| $14.10 Nov 18, 2026 | $1.54B | 97 5-pillar Nov 18, 2026 | |
| $18.40 Nov 18, 2026 | $1.31B | 96 5-pillar Nov 18, 2026 | |
| $33.11 Nov 18, 2026 | $1.94B | 96 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $47.40 Nov 19, 2026 | $1.41B | 76 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $40.04 Nov 19, 2026 | $1.30B | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $18.52 Nov 19, 2026 | $1.14B | 66 5-pillar Nov 18, 2026 | |
| SpyGlass Pharma (SGP) — this page | $30.78 | $1.03B | 64 |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $37.00 – $44.00
- Consensus target
- $40.00
- Median target
- $39.00
- Revenue estimate
- $0.00
- EPS estimate
- $-2.73
Consensus record · Captured .
Measured against a quoted price of $30.78 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SGP in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SGP in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about SpyGlass Pharma (SGP)?
Investor Questions: SGP Stock
These answers are editorial: 1 of these 9 answers is drawn from the SGP research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for SGP?
SGP carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. SpyGlass Pharma, Inc. is an advanced biopharmaceutical company focused on developing innovative therapeutic approaches for chronic eye conditions.
Is SGP a good stock to buy?
Stock Expert AI does not rate SGP buy, sell or hold. SpyGlass Pharma, Inc. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SGP stock price today?
The last price recorded for SpyGlass Pharma, Inc. (SGP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the SGP price target?
The analyst consensus price target for SpyGlass Pharma, Inc. (SGP), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for SGP?
The main risks for SpyGlass Pharma, Inc. are inherent to its nature as a clinical-stage biopharmaceutical company heavily reliant on a single lead product, the Bimatoprost Drug Pad-IOL System.
What are the key factors to evaluate for SGP?
SpyGlass Pharma, Inc. (SGP) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Focus on chronic eye conditions with its flagship Bimatoprost Drug Pad-IOL System, addressing a significant unmet medical need in ophthalmology. Not financial advice.
How frequently does SGP data refresh on this page?
SGP's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SGP's recent stock price performance?
SpyGlass Pharma, Inc. (SGP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Bimatoprost Drug Pad-IOL System addressing a significant unmet need in chronic eye conditions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGP overvalued or undervalued right now?
SpyGlass Pharma, Inc. (SGP) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 9 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com